Clinical trials: Radical Prostatectomy
- Condition Radical Prostatectomy
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Prostate Cancer, Prostate Adenocarcinoma
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic
- Trial name
- CONDOR (NCT03739684)
- Testing
- 18F-DCFPyL, PET/CT Imaging
- Where
- 14 sites in United States, Canada
- Volunteers
- 208 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Erectile Dysfunction
Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy
The objectives of this study are to evaluate the safety and efficacy of two doses of avanafil in the treatment of adult males for erectile dysfunction following bilateral nerve-sparing radical prostatectomy.
- Trial name
- NCT00895011
- Testing
- Avanafil
- Where
- 51 sites in United States
- Volunteers
- 298 people
- Sponsor
- VIVUS LLC
Prostate Cancer
A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
The purpose of this study is to assess the benefit of immediate hormonal treatment after Radical Prostatectomy in Chinese and Russian patients with high risk prostate cancer.
- Trial name
- PRIORITI (NCT01753297)
- Testing
- Triptorelin 11.25 mg
- Where
- 18 sites in China, Russia
- Volunteers
- 226 people
- Sponsor
- Ipsen
Prostate Cancer
A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology
This was a multicenter, multi-reader, open-label, Phase 2 study assessing the safety and performance characteristics of MIP 1404 imaging in the detection of prostate gland and pelvic lymph node cancer.
- Trial name
- NCT01667536
- Testing
- Drug: 99mTc-MIP-1404
- Where
- 35 sites in United States, Belgium and 6 more
- Volunteers
- 105 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Prostate Cancer
Global Performance Evaluation of the AMS CONTINUUM™ Device
1. To evaluate Device performance in providing mucosa to mucosa apposition to facilitate sustainable vesico-urethral anastomosis during a radical prostatectomy procedure. 2.
- Trial name
- NCT01083199
- Testing
- CONTINUUM™
- Where
- 2 sites in Greece, Spain
- Volunteers
- 10 people
- Sponsor
- American Medical Systems
Erectile Dysfunction
A Study of Tadalafil After Radical Prostatectomy
The study will include patients with localized prostate cancer who experience erectile dysfunction following bilateral nerve-sparing radical prostatectomy.
- Trial name
- REACTT (NCT01026818)
- Testing
- Tadalafil
- Where
- 52 sites in Belgium, Canada and 8 more
- Volunteers
- 583 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer
The goal of this clinical research study is to find out how treatment with abiraterone acetate in combination with prednisone and a Luteinizing Hormone-Releasing Hormone (LHRH) analogue changes the tumor in comparison to…
- Trial name
- NCT01088529
- Testing
- Abiraterone Acetate, Prednisone, LHRHa
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Cougar Biotechnology, Inc.
Prostate Cancer
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with…
- Trial name
- OSPREY (NCT02981368)
- Testing
- 18F-DCFPyL Injection, PET/CT imaging
- Where
- 10 sites in United States, Canada
- Volunteers
- 385 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Erectile Dysfunction, Prostate Cancer
A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
The purpose of the study is to compare the safety and effectiveness of Prograf in the prevention of erectile dysfunction in men after a radical prostatectomy.
- Trial name
- NCT00106392
- Testing
- Tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 131 people
- Sponsor
- Astellas Pharma Inc
Urinary Incontinence
A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy
The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment of solifenacin succinate versus placebo in participants who are incontinent after Robotic Assisted Radical Prostatectomy.
- Trial name
- NCT01371994
- Testing
- solifenacin succinate
- Where
- 60 sites in United States, Canada
- Volunteers
- 640 people
- Sponsor
- Astellas Pharma Inc
Stress Urinary Incontinence
A Post-Market Study of the AMS AdVance™ Male Sling System for the Treatment of Male Stress Urinary Incontinence
A prospective, multi-center study of the AdVance Male Sling for Stress Urinary Incontinence. The purpose of this study is to obtain surgical technique data for use in physician education and training and to collect early clinical…
- Trial name
- NCT00998790
- Testing
- American Medical Systems (AMS) AdVance™ Male Sling System
- Where
- 3 sites in Belgium, France
- Volunteers
- 114 people
- Sponsor
- Boston Scientific Corporation
Urinary Incontinence, Prostate Cancer
Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling
The purpose of this study is to determine the impact of an absorbable urethrovesical sling on the post-operative return of urinary continence after robot-assisted radical prostatectomy.
- Trial name
- NCT00937833
- Testing
- Prostatectomy, Surgisis Male Sling
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Cook Group Incorporated
Prostate Cancer, Prostate Adenocarcinoma
Trial of NanoPac Focal Therapy for Prostate Cancer
This study evaluates the use of NanoPac injected directly into the prostate lesion in men with prostate cancer.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Adenocarcinoma, Prostatic Neoplasm
- Trial name
- NCT04221828
- Testing
- NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- NanOlogy, LLC
Prostatic Neoplasms
Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy
This is a prospective, multicenter, open-label, randomized phase III study in participants at high risk of recurrent prostate cancer after radical prostatectomy.
- Trial name
- NCT00283062
- Testing
- Docetaxel (TAXOTERE®) Chemotherapy, Leuprolide acetate ( ELIGARD®) Hormonal Therapy
- Where
- 17 sites in United States, Australia and 15 more
- Volunteers
- 228 people
- Sponsor
- Sanofi
Prostate Cancer
PROvenge Treatment and Early Cancer Treatment
The PROTECT-PROvenge Treatment and Early Cancer Treatment trial was a Phase III trial for patients with hormone sensitive prostate cancer. The study was conducted at over 15 participating centers throughout the US.
- Trial name
- PROTECT (NCT00779402)
- Testing
- Control, Sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 176 people
- Sponsor
- Dendreon
Prostate Cancer
Performance Evaluation of the AMS CONTINUUM™ Device
1. To assess the safety of using the CONTINUUM™ device by monitoring the side effects and complications associated with the Device following a radical prostatectomy. 2.
- Trial name
- NCT00894933
- Testing
- CONTINUUM™
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- American Medical Systems
Adenocarcinoma of the Prostate
Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
Open-label, dose rising, Phase IIa trial of intratumorally-injected NanoPac® 6, 10, or 15 mg/mL in subjects with prostate cancer scheduled for prostatectomy.
- Trial name
- NCT03077659
- Testing
- NanoPac®
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- NanOlogy, LLC
Lymphoceles Following Pelvic Lymph Node Dissection
Cold Plasma for the Reduction of Lymphoceles Following PLND
This study protocol will evaluate the efficacy of Bovie Medical's J-Plasma® helium based plasma technology in the reduction of lymphoceles following pelvic lymph node dissection (PLND) during robotic assisted radical…
- Trial name
- NCT02658851
- Testing
- J-Plasma
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Apyx Medical
Prostatic Neoplasms
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
Main Study: The purpose of main study is to assess if the combination of apalutamide and androgen deprivation therapy (ADT) in participants with high-risk localized prostate cancer improves the biochemical recurrence (BCR) free…
- Trial name
- NCT04523207
- Testing
- Apalutamide, ADT, Relugolix
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Janssen Research & Development, LLC
Pain, Postoperative
Morphine-Sparing Efficacy Of Parecoxib In Pain Treatment After Radical Prostatectomy
The primary objective of this study is to demonstrate the opioid-sparing efficacy of parecoxib 40 mg intravenously given as a loading dose followed by 20 mg intravenously in the 24 hours after the end of surgery.
- Trial name
- PROSTATECTOMY (NCT00346268)
- Testing
- Morphine, Parecoxib
- Where
- 4 sites in Germany
- Volunteers
- 105 people
- Sponsor
- Pfizer